Integrated plasmid engineering and manufacturing process: a unified approach from lab to clinic
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
The advancement of gene therapy hinges on the ability to engineer and manufacture plasmids with precision, efficiency, and scalability. In this webinar, a successful approach for plasmid engineering and manufacturing is highlighted, using the genesis of a novel helper plasmid for AAV production to illustrate an integrated process.
Prototyping various plasmids (including those with the capacity to handle complex features such as inverted terminal repeats and hairpins) and optimizing the manufacturing process allows for the same engineered product to be used seamlessly throughout all development phases. Emphasizing the importance of continuity, this method eliminates the common industry challenges faced when transitioning from discovery grade to higher-quality production, such as High-Quality (HQ) or GMP grade.
This integrated approach ensures the integrity of the therapeutic product from lab research to clinical phases, offering a robust platform to propel gene therapy projects forward with confidence.
- How to engineer plasmids using innovative technology
- How to optimize the manufacturing process by depending on plasmid features
- How to de-risk processes and make them cost-effective
SPEAKERS
You might also like
Industry highlights: switching from manual to automated hematopoietic stem cell (HSC) gene engineering
Improving AAV productivity and packaging efficiency for transient and producer cell lines through plasmid engineering
From the lab to the bench, scaling up regulatory T cell therapy
